IL10 and chronic obstructive pulmonary disease: In addition, the magnitude of the increase in IL-10 levels was significant in patients with COPD treated with simvastatin compared with subjects treated with placebo (mean difference, 24.7 pg/mL; 95% CI, 15.9-33.6; P < .001) (Fig 3A, Table 3).